Philips-Azurion-lung-ablation

Philips-Azurion-Lung-Edition

September 21, 2020

Philips Azurion Lung Edition supports high precision diagnosis and minimally invasive therapy in one room

Amsterdam, the Netherlands Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today introduced Azurion Lung Edition, an advanced 3D imaging and navigation platform to accelerate the diagnosis and treatment of lung cancer. The suite combines CT-like 3D images acquired at the tableside (Cone Beam CT) with live X-ray guidance and advanced tools to support image-guided lung procedures. The system is designed specifically for bronchoscopy procedures, enabling clinicians to perform both minimally invasive endobronchial biopsies and lesion ablation during the same procedure. By speeding diagnosis and treatment, Azurion Lung Edition is helping to transform lung cancer care, contributing to dramatically improved outcomes and reduced costs.

Each year 1.7 million people die worldwide of lung cancer, making it the leading cause of cancer deaths globally [1] and accounting for more loss of life than breast, colon and prostate cancer combined. Today, over 60% of patients are diagnosed at a late stage, with a small chance of a surgical cure. But thanks to a rise in the number of lung cancer screening programs and increasing patient awareness, a growing proportion of patients have small peripheral lesions that are operable.

In addition to early diagnosis, fast treatment is critical to ensure better outcomes and quality of life for lung cancer patients, with every week of delay resulting in a 5% increase in mortality [2]. Today, most patients face a long journey to a definitive diagnosis and they often undergo a painful recovery after open surgery. Cone Beam CT is seen as the gold standard for clinicians to both diagnose and treat lung cancer in one room, and even during the same procedure.

This is a very exciting time in the world of interventional pulmonology and advanced bronchoscopy, said Dr. Michael Pritchett, pulmonary and critical care physician, Director, Chest Center of the Carolinas, FirstHealth Moore Regional Hospital, Pinehurst Medical Clinic, U.S. One of the things that were particularly excited about is being able to diagnose patients, stage their cancer and treat them, all in a single procedure. As a diagnostic bronchoscopist its exciting and rewarding to be able not only to diagnose patients, but to go on to treat them as well.

Lung cancer is one of the most aggressive forms of cancer, and we need innovative technology to fight back, said Dr. Gustavo Cumbo-Nacheli, Director of Bronchoscopy and Interventional Pulmonology at Spectrum Health in Grand Rapids, Michigan, U.S. Without a Cone Beam CT scan to confirm placement of the biopsy needle, repeat procedures are often necessary. And by combining Cone Beam CT with other technologies, including robotics, we will be able to go beyond biopsy and treat the patient.

On Wednesday, September 23 at 13:00 ET (19:00 CET). Dr. Atul Gupta, Interventional Radiologist and Chief Medical Officer, Philips Image Guided Therapy, will host an exclusive virtual roundtable together with a panel of renowned pulmonologists and interventional radiologists, The Future Now: Implementing Cone Beam CT-guided endobronchial ablation therapy. To register, click here.

Image-guided minimally invasive procedures continue to expand into new treatment areas, enabled by sophisticated, procedure-oriented solutions like Azurion Lung Edition, said Dr. Gupta. With lung cancer increasingly being detected at an earlier stage, new minimally invasive treatment strategies like ablation have the potential to significantly improve outcomes for patients.

Intuitive, integrated and efficient, the Azurion platform optimizes clinical and operational lab performance and expands the role of image-guided interventions in the treatment of patients. The platform has achieved rapid global adoption and has been used in well over two million procedures [3] worldwide.

Philips Azurion Lung Edition is available now in the U.S.

[1] American Cancer Society: Cancer Facts & Figures 2013. [2] Kanarek et al., Survival after community diagnosis of early-stage non-small cell lung cancer. The American journal of medicine. 127, no. 5 (2014): 443-449.[3] Based on Philips internal case and procedure data.

For further information, please contact:

Mark GrovesPhilips Global Press OfficeTel: +31 631 639 916Email: mark.groves@philips.com

Twitter: mark_groves

Fabienne van der FeerPhilips Image Guided TherapyTel: +31 622 698 001Email: fabienne.van.der.feer@philips.com

Twitter: FC_Feer

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found atwww.philips.com/newscenter.

Go here to see the original:
Philips paves the way for faster lung cancer diagnosis and treatment with advanced 3D imaging and navigation platform - GlobeNewswire